**EXKIVITY**
**(mobocertinib)**

# Pre - PA Allowance

None

_____

# Prior-Approval Requirements

**Age**          18 years of age and older

**Diagnosis**

Patient must have the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)
    a. EGFR exon 20 insertion mutation as detected by an FDA-approved test
    b. Disease has progressed on or after platinum-based chemotherapy

**AND ALL** of the following:
1. Prescriber agrees to monitor for QTc prolongation and risk factors for QTc prolongation before initiation of treatment and periodically during treatment
2. Female patients of reproductive potential **only**: pregnancy will be excluded before start of treatment and patient will be advised to use effective non-hormonal contraception during treatment with Exkivity and for 1 month after the last dose

    Male patients with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Exkivity and for 1 week after the last dose

# Prior - Approval Limits

**Quantity**

| Drug | Quantity per 90 days |
|------|----------------------|
| Exkivity 40mg | 360 capsules |

**Duration**     12 months

_____

# Prior – Approval *Renewal* Requirements

**Age**          18 years of age and older

**Diagnosis**

**EXKIVITY**
**(mobocertinib)**

Patient must have the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)
   a. EGFR exon 20 insertion mutation as detected by an FDA-approved test

**AND ALL** of the following:
1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to monitor for QTc prolongation and risk factors for QTc prolongation periodically during treatment
3. Female patients of reproductive potential **only**: patient will be advised to use effective non-hormonal contraception during treatment with Exkivity and for 1 month after the last dose
4. Male patients with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Exkivity and for 1 week after the last dose

# Prior - Approval *Renewal* Limits

Same as above